With a market capitalization (market cap) of $1.48B — a measure of how much the company is worth — Taysha Gene Therapies, Inc. ranks #2,254 among the 2,510 companies tracked, and 305th in Healthcare as of October 3, 2026. Shares trade at $4.63, down 2.32% on the day.
of 2,510 tracked
Market-cap change uses historical capitalization records. Share-price returns are a different series — they can diverge when the share count changes. Those returns are not a CAGR until you pick a start value, an ending value, and years. CAGR calculator. Market cap vs. stock price.
Year-end values and the chart both come from historical market-cap records, not from applying today's share count to past prices. Latest historical observation October 2, 2026. Ranking headline cap is the snapshot figure as of October 3, 2026.
| Year | As of | Market cap | Annual change | Year-end close |
|---|---|---|---|---|
| 2026 | Oct 2, 2026 | $1.71B | -2.70% | $4.63 |
| 2025 | Dec 31, 2025 | $1.76B | +332.81% | $5.50 |
| 2024 | Dec 31, 2024 | $405.72M | +40.79% | $1.73 |
| 2023 | Dec 29, 2023 | $288.17M | +159.68% | $1.77 |
Ranking figure $1.48B as of October 3, 2026.
Taysha Gene Therapies, Inc.'s ranking market cap is the provider-reported capitalization on the same snapshot as the rest of this site, with a share price of $4.63 as of October 2, 2026. Charts and the year-end table use a separate historical market-cap series, last observed at $1.71B on October 2, 2026. See how the ranking works.
The ranking snapshot ($1.48B as of October 3, 2026) is FMP company-screener market cap. The historical observation ($1.71B on October 2, 2026) is FMP historical-market-capitalization for the same ticker. The live quote market cap agrees with the ranking snapshot. This page does not replace one series with the other.
Live shares outstanding are not on the quote used for price, so this page does not invent a current share count. Shares outstanding vs. float.
The latest annual report (FY 2025) used a weighted-average 319,711,972 shares. That figure is an average for the year, not the live count in the market-cap formula.
Book equity: assets minus liabilities on the latest annual report.
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
Not in this snapshot
FY 2025 net worth
Largest U.S.-listed names in the same FMP sector — not a hand-picked competitor set.
| Rank | Company | Market cap | 1D |
|---|---|---|---|
| #14 | Eli Lilly and Company LLY | $1.08T | -0.61% |
| #21 | Johnson & Johnson JNJ | $617.01B | -1.02% |
| #24 |
Taysha Gene Therapies, Inc. is a biotech firm specializing in the creation and market introduction of gene therapies that utilize adeno-associated virus (AAV) vectors. Its core mission is to tackle inherited diseases affecting the central nervous system (CNS).
Summary from the company profile (Financial Modeling Prep). Principal financial figures above are for FY 2025.
Visit websiteAs of October 3, 2026, Taysha Gene Therapies, Inc. (TSHA) is worth $1.48B — that is its market capitalization, the total value of its outstanding shares on MarketCapLens.
A company’s net worth is its shareholders’ equity: assets minus liabilities on the balance sheet. That is book equity, not market cap. For FY 2025, Taysha Gene Therapies, Inc.’s book equity is about $246.94M. Market cap is the market value of the outstanding shares. As of October 3, 2026, its market cap is $1.48B. Book equity is an accounting remainder; market cap is a trading value. Neither is a person’s net worth.
Taysha Gene Therapies, Inc. ranks #2,254 among the 2,510 companies tracked on MarketCapLens. In Healthcare it ranks #305 of 350.
Fundamentals are annual. Figures labeled with their fiscal year. Live ratios use the current price against those annual earnings.
Over the past year, market cap and share price moved by different amounts. Share count can change independently of price. What changes market cap.
| 2022 |
|---|
| Dec 30, 2022 |
| $110.97M |
| -71.35% |
| $2.26 |
| 2021 | Dec 31, 2021 | $387.29M | — | $11.65 |
|---|
Last observation of each calendar year from historical market-cap records. The current year is through the latest date, not a completed year-end. Share-price close is the matching session for context — we do not rebuild cap from today's share count.
Not in this snapshot
FY 2025
| $464.35B |
| +1.11% |
| #36 | Merck & Co., Inc. MRK | $356.4B | +0.34% |
| #38 | UnitedHealth Group Incorporated UNH | $337.74B | +1.83% |
| #52 | Novartis AG NVS | $268B | -0.04% |
Companies immediately above and below in the overall ranking. They may be in a different sector.
| Rank | Company | Market cap | 1D |
|---|---|---|---|
| #2251 | Alkami Technology, Inc. ALKT | $1.49B | -1.07% |
| #2252 | Ardent Health Inc. ARDT | $1.48B | +0.88% |
| #2253 | ICF International, Inc. ICFI | $1.48B | -3.66% |
| #2255 | Revolve Group, Inc. RVLV | $1.48B | -2.26% |
| #2256 | FuelCell Energy, Inc. FCEL | $1.48B | +11.47% |
| #2257 | Corsair Gaming, Inc. CRSR | $1.47B | -0.43% |
Taysha Gene Therapies, Inc.’s ranking market cap of $1.48B comes from the same snapshot as the rest of this site, as of October 3, 2026. It is not share price multiplied by the FY 2025 weighted-average share count of 319,711,972. The ranking snapshot ($1.48B as of October 3, 2026) is FMP company-screener market cap. The historical observation ($1.71B on October 2, 2026) is FMP historical-market-capitalization for the same ticker. The live quote market cap agrees with the ranking snapshot. This page does not replace one series with the other.
Over the past year, Taysha Gene Therapies, Inc.’s market cap is up 25.76%, using historical market-cap records rather than today’s share count applied to past prices.
Taysha Gene Therapies, Inc. (TSHA) shares trade at $4.63, down 2.32% on the day, as of October 3, 2026.
Live P/E is share price divided by annual earnings per share. It is blank when earnings are missing, zero, or negative — not a 0× multiple.